Recent Development News: Q3 – 2018

Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

BALTIMORE, Oct. 31, 2018 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has submitted … Continue reading

Posted in Recent Development News: Q3 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Begins U.S. IPO Effort

CNTX intends to raise $86.25 million in gross proceeds from an IPO of its common stock, not including customary underwriter options. No existing shareholders have indicated an interest to purchase shares of the IPO, although I would expect to see … Continue reading

Posted in Recent Development News: Q3 - 2018, Recent Developments | Comments Off